9334 Federal Register / Vol. 60, No. 33 / Friday, February 17, 1995 / Notices

Capitol Street, NW., 9th Floor.

Interested parties may submit comments

on each agreement to the Secretary,

Federal Maritime Commission,

Washington, DC 20573, within 10 days

after the date of the Federal Register in

which this notice appears. The

requirements for comments are found in

§ 572.603 of Title 46 of the Code of

Federal Regulations. Interested persons

should consult this section before

communicating with the Commission

regarding a pending agreement.

Agreement No.: 202–011432–003.

Title: Pacific Latin America

Agreement.

Parties:

Sea-Land Service, Inc.

Central American Container Line,

S.A.

A.P. Moller-Maersk Line

Synopsis: The proposed amendment

deletes Central America Container Line,

S.A., changes the notification period for

independent action from two days to

five days and authorizes the Conference

Chairman or his designee to sign and

file any amendments to the basic

Agreement.

Dated: February 13, 1995.

By Order of the Federal Maritime

Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 95–3981 Filed 2–16–95; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL MARITIME COMMISISON

[Docket No. 95–03]

Puerto Rico Frieght Systems, Inc. v. R

& S Trading and J.C. Trading; Notice

of Filing of Complaint and Assignment

Notice is given that a complaint filed

by Puerto Rico Freight Systems, Inc.

(‘‘Complainant’’) against R & S Trading

and J.C.Trading (‘‘Respondents’’) was

served February 14, 1995. Complainant

alleges that Respondents have violated

sections 3, 14, 15, 16, 17, and 18 of the

Shipping Act of 1916, 46 U.S.C. app.

804, 812, 814, 815, 816 and 817(b)(1), by

issuing false manifests, shipping

materials in containers which are not

manifested or declared by Respondents,

operating without a tariff, waiving fees

for ocean freight, competing with other

freight operators who adhere to a tariff

to their disadvantage, and operating

without bills of lading.

This proceeding has been assigned to

the office of Administrative Law Judges.

Hearing in this matter, if any is held,

shall commence within the time

limitations prescribed in 46 CFR 502.61,

and only after consideration has been

given by the parties and the presiding

officer to the use of alternative forms of

dispute resolution. The hearing shall

include oral testimony and crossexamination in the discretion of the

presiding officer only upon proper

showing that there are genuine issues of

material fact that cannot be resolved on

the basis of sworn statements, affidavits,

depositions, or other documents or that

the nature of the matter in issue is such

that an oral hearing and crossexamination are necessary for the

development of an adequate record.

Pursuant to the further terms of 46 CFR

502.61, the initial decision of the

presiding officer in this proceeding shall

be issued by February 14, 1996, and the

final decision of the Commission shall

be issued by June 14, 1996.

Joseph C. Polking,

Secretary.

[FR Doc. 95–4027 Filed 2–16–95; 8:45 am]

BILLING CODE 6730–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Committee on Vital and Health

Statistics: Meeting

Pursuant to Pub. L. 92–463, the

National Center for Health Statistics

(NCHS), Centers for Disease Control and

Prevention (CDC), announces the

following committee meeting.

Name: National Committee on Vital and

Health Statistics (NCVHS).

Times and Dates: 1 p.m.–5 p.m., March 8,

1995; 9 a.m.–5 p.m., March 9, 1995; 9 a.m.–

3 p.m., March 10, 1995.

Place: Room 703A, Hubert H. Humphrey

Building, 200 Independence Avenue, SW,

Washington, D.C. 20201.

Status: Open.

Purpose: The purpose of this meeting is for

the committee to consider reports from each

NCVHS subcommittee; to receive reports

from offices of the Department of Health and

Human Services; to explore information

needs for health reform; and to address new

business as appropriate.

Contact Person for More Information:

Substantive program information as well as

summaries of the meeting and a roster of

committee members may be obtained from

Gail F. Fisher, Ph.D., Executive Secretary,

NCVHS, NCHS, CDC, Room 1100,

Presidential Building, 6525 Belcrest Road,

Hyattsville, Maryland 20782, telephone 301/

436–7050.

Dated: February 13, 1995.

William H. Gimson,

Acting Associate Director for Policy

Coordination, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 95–3999 Filed 2–16–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95M–0023]

Molecular Biosystems, Inc.; Premarket

Approval of Albunex

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing its

approval of the application by

Molecular Biosystems, Inc., San Diego,

CA, for premarket approval, under the

Federal Food, Drug, and Cosmetic Act

(the act), of Albunex. After reviewing

the recommendation of the Radiological

Devices Panel, FDA’s Center for Devices

and Radiological Health (CDRH)

notified the applicant, by letter of

August 5, 1994, of the approval of the

application.

DATES: Petitions for administrative

review by March 20, 1995.

ADDRESSES: Written requests for copies

of the summary of safety and

effectiveness data and petitions for

administrative review to the Dockets

Management Branch (HFA–305), Food

and Drug Administration, rm. 1–23,

12420 Parklawn Dr., Rockville, MD

20857.

FOR FURTHER INFORMATION CONTACT:

Robert Phillips, Center for Devices and

Radiological Health (HFZ–470), Food

and Drug Administration, 9200

Corporate Blvd., Rockville, MD 20850,

301–594–1212.

SUPPLEMENTARY INFORMATION: On

February 5, 1991, Molecular Biosystems,

Inc., San Diego, CA 92121, submitted to

CDRH an application for premarket

approval of Albunex. The device,

which is a suspension of air-filled

microspheres made from sonicated 5

percent human albumin, is an

ultrasound contrast media that is used

as an aid for ultrasound contrast

enhancement of ventricular chambers

and improvement of endocardial border

definition in patients with suboptimal

echoes undergoing ventricular function

and regional wall motion studies.

On July 29, 1992, the Radiological

Devices Panel of the Medical Devices

Advisory Committee, an FDA advisory

committee, reviewed and recommended

approval of the application. On August